| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Clinical Development | SVP, Clinical Development
1 company
Xu Cong Claire serves as an EVP, Clinical Development at NBP. Across recent SEC filings that breaks down to 0 buys and 3 sells. Those positions are worth an estimated $240K at current prices.
The biggest single holding is NBP (~$240K) as EVP, Clinical Development. The recent filings there lean toward selling, a net 11,261 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | NBP Novabridge Biosciences | EVP, Clinical Development | Sale+OE | 3,282 | $0.79 | $2,592.78 | -1.1% | - | - | |
| Jul 6, 2026 | NBP Novabridge Biosciences | SVP, Clinical Development | Sale+OE | 4,485 | $0.89 | $3,991.65 | -1.5% | -32.3% | - | |
| Jun 1, 2026 | NBP Novabridge Biosciences | SVP, Clinical Development | Sale+OE | 3,494 | $3.94 | $13,766.36 | -1.2% | +6.4% | - |